Komori
Almedio (7859) · RiskMaterialisedLatest Earnings (2026-11-02): "Mitigated"

Investment burden from new businesses and delayed monetization

First written in FY2016. 10 of 31 entries say "Materialised", first in FY2017-Q1. Latest entry: 2026-11-02.

31entries
11years
4from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2020-Q2 – FY2021-Q1MitigatedFY2024-Q1 – FY2026-H12016: 320162017: 320172018: 320182019: 320192020: 220202021: 320212022: 320222023: 320232024: 220242025: 120252026: 52026
Same theme, other companies
Delayed Monetization Associated with Expansion into New Service AreasA theme 35 companies write about · 35 as a headwind · 0 as a tailwind

Almedio moved to the "Worse" side of this theme in 2017, 6 years before the typical company in this theme (2023).

The whole theme swung hardest in 2025: 6 of 15 companies on the "Worse" side.

2 other companies' latest entry also says "Mitigated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 35 companies compared. The sentences above are computed from all 35.
Full recordFilings, disclosures and news, newest first
  1. 2026-11-02MitigatedEarnings

    「なお、資源・材料販売における大型案件の本格採用については、顧客側で生産計画の最終調整に入っています。」

    大型案件は本格採用完了には至っていないが、顧客側の生産計画が最終調整段階まで進み、収益化遅延リスクは前進を示している。
  2. FY2026MaterialisedAnnual report

    「Resource and materials sales progressed steadily as the number of orders increased. However, 2 of the projects expected to proceed to full-scale adoption during the current fiscal year were postponed to the next fiscal year because of changes in the customers' production plans, resulting in performance below plan for the current fiscal year.」

    Regarding the delayed monetization risk of the new business, 2 projects expected to proceed to full-scale adoption were pushed into the next fiscal year because of changes in the customers' production plans, resulting in performance below plan for the current fiscal year.
  3. FY2026-H1MitigatedAnnual report

    「For customers expected to proceed with full-scale adoption, the Company is conducting sales activities to obtain their production and ordering plans. In addition, moves toward full-scale adoption have emerged in the sale of resources and materials.」

    Regarding the delayed monetization risk of the new business, the disclosure describes sales activities aimed at obtaining customers' production and ordering plans, as well as progress in resource and materials sales toward full-scale adoption.
  4. FY2025-H1MitigatedAnnual report

    「The Company sold samples for a fee, and the range of industries conducting evaluations is expanding both in Japan and overseas. In the heat-dissipation materials field, some chemical-materials manufacturers among customers with a high likelihood of full-scale adoption have moved to the specification-confirmation phase after receiving favorable evaluation results. The Company sold samples in larger lots than before.」

    In the Nanomaterials business, the range of industries covered by evaluations expanded, customers moved into the specification-confirmation phase, and samples were sold in larger lots, indicating progress in addressing the delayed monetization risk. However, there is no statement that full-scale mass-production adoption had been completed.
  5. FY2024-Q3MitigatedAnnual report

    「The Company sold samples for a fee and received favorable evaluation results on multiple projects. In some projects, the evaluation cycle became shorter, while some customers used a substantial quantity of material in a single evaluation. Additional orders and sample shipment volumes increased.」

    In the Nanomaterials business, improved evaluation results, additional orders and increased sample shipment volumes indicated progress in addressing the delayed monetization risk. However, there is no statement that mass-production adoption had been completed.
  6. FY2024-Q1MitigatedAnnual report

    「The Company sold samples for a fee and received favorable evaluation results on multiple projects. Additional orders and the volume of samples shipped per project increased.」

    In the Nanomaterials business, favorable evaluation results on multiple projects led to increases in additional orders and sample shipment volumes. Although there is no statement that mass production had been completed, progress was indicated in addressing the delayed monetization risk.
  7. FY2023MaterialisedAnnual report

    「In the consolidated fiscal year, the carrying amounts of assets showing a decline in profitability were reduced to their recoverable amounts, and the resulting reduction of ¥154.881 million was recorded as an impairment loss under extraordinary losses.」

    The Company recorded an impairment loss of ¥154.881 million due to declining profitability at the Higashimurayama site and Fukushima-Futaba plant of the new Nanomaterials business, among other assets.
  8. FY2023-Q3MitigatedAnnual report

    「In these circumstances, we secured adoption of our material for use in semiconductor manufacturing equipment in the industrial sector. Although the volume of the adopted material remains small, CNF applications are expected not only in the aerospace and automotive-related markets but also in the industrial sector. Using this adoption as a foothold, we will promote horizontal sales expansion.」

    The Nanomaterials business moved from the sample evaluation stage to actual adoption and sales expansion after full-scale adoption was approved. The volume of the adopted material is still small, according to the disclosure.
  9. FY2023-Q2MitigatedAnnual report

    「As a result of these initiatives, some customers progressed to the stage of final testing and scale-up testing. As a result, sales exceeded those in the same quarter of the previous year.」

    In the Nanomaterials business, customer evaluations progressed to final testing and scale-up testing, indicating progress in addressing the delayed monetization risk. However, there is no statement that full-scale adoption had been completed.
  10. FY2023-Q1MitigatedAnnual report

    「In addition, a chemical manufacturer that sells reagents and other products registered the Company's products and began selling them, creating more opportunities for researchers and developers in Japan and overseas to obtain the Company's products. As a result, sales exceeded those in the same quarter of the previous year.」

    Nanomaterials products were registered and began being sold by a chemical manufacturer, expanding sales opportunities. Progress was reported in addressing the delayed monetization risk of the new business, but sales remained at ¥4 million.
  11. FY2022-Q3MaterialisedAnnual report

    「The Company sold samples for a fee. As sample evaluations progressed, it began receiving strong inquiries, particularly from the aerospace, automotive and infrastructure industries. It also agreed to conclude a joint development agreement with a leading aerospace company and to extend a confidentiality agreement with a leading automotive company. The number of sample shipments to a broad range of industries in Japan and overseas increased, as did the number of customers considering multiple applications within a single company. As a result, sales exceeded those in the same quarter of the previous year, although they were below plan for the quarter.」

    In the Nanomaterials business, sample shipments, evaluations and inquiries progressed, but performance was below plan for the quarter. The situation in which monetization of the new business continues to fall short of plan also continued.
  12. FY2022-Q2MaterialisedAnnual report

    「The Company sold samples for a fee. Although sales were below plan, partly because some sales were pushed into the third-quarter accounting period due to changes in delivery formats and other factors, they exceeded sales in the same quarter of the previous year.」

    In the Nanomaterials business, sales were pushed into the third quarter due to changes in delivery formats and other factors, resulting in a delay in monetization and performance below plan. Sales, however, exceeded those in the same period of the previous year.
  13. FY2022-Q1RestatedAnnual report

    「The Company sold samples for a fee. Although sales were below plan, they exceeded sales in the same quarter of the previous year. Several dozen customers are continuing their evaluations, and the number of customers newly beginning evaluations is increasing.」

    In the Nanomaterials business, sample sales and customer evaluations are progressing, but performance is below plan, and the business remains on the way to mass production and stable monetization.
  14. FY2021MaterialisedAnnual report

    「In the consolidated fiscal year, the Company recorded an impairment loss of ¥82.960 million. The recoverable amount was calculated based on value in use, which was determined to be zero.」

    For assets with declining profitability, including those related to the new business, value in use was determined to be zero and an impairment loss of ¥82.960 million was recorded. The investment burden and delayed monetization risk of the new business materialized as an accounting loss.
  15. FY2021-Q1RestatedAnnual report

    「The Nanomaterials business commercializes powdered carbon fiber. Although sales for mass production have yet to materialize, the track record of prototype evaluations is growing.」

    In the Nanomaterials business, the track record of prototype evaluations is growing, but sales for mass production have yet to materialize, and the situation in which monetization is taking time continues.
  16. FY2020-Q3RestatedAnnual report

    「The Nanomaterials business commercializes powdered carbon fiber. Although paid sample shipments and inquiries from customers continued to increase, customer evaluations and verification processes remained at the evaluation stage, and there were no sales for mass production.」

    In the Nanomaterials business, sample shipments and inquiries increased, but sales for mass production have yet to materialize, and the situation in which monetization is taking time continues.
  17. FY2020-Q2RestatedAnnual report

    「Although paid sample shipments and inquiries from individual customers continued to increase, the products remained at the evaluation stage in customers' assessment and verification processes, and there were no sales for mass production.」

    In the nanomaterials business, sample shipments and inquiries continued, but sales for mass production had still not been achieved.
  18. FY2020-Q1MaterialisedAnnual report

    「Although paid sample shipments and inquiries from individual customers increased, the products remained at the evaluation stage in customers' assessment and verification processes, and there were no sales for mass production.」

    In the new nanomaterials business, there were inquiries and paid sample shipments, but sales for mass production had not been achieved, demonstrating that monetization would take time.
  19. FY2019WorsenedAnnual report

    「If a new business that has been launched fails to progress as planned due to changes in market conditions, customer trends or other factors, the funds invested may not be recoverable, which may adversely affect the Group's operating performance.」

    The WEB Business experienced weak performance, an impairment loss of ¥224 million and a loss of ¥142 million on the transfer of the business, while delays in the launch of operations continued in the China vending machine business. The investment burden and delayed monetization risks of new businesses have become more concrete.
  20. FY2019-Q2MaterialisedAnnual report

    「The business environment changed due to various factors, including soaring advertising costs, and performance continued to stagnate. As results remained substantially below the initial budget, the Group transferred the WEB Business on 30 September 2018 while working to strengthen its management structure as part of its business restructuring efforts.」

    The delayed monetization and continued weak performance of the new WEB business ultimately led to the transfer of the business.
  21. FY2019-Q1MaterialisedAnnual report

    「Following a renewed assessment of the recoverability of the WEB Business, a decline in profitability was identified, and an impairment loss of ¥129 million was recognized as an extraordinary loss.」

    The delayed monetization and decline in profitability of the new WEB business materialized in the recognition of a ¥129 million impairment loss.
  22. FY2018-Q3RestatedAnnual report

    「However, sales fell short of plan because the delayed full-scale launch of operations during the second quarter of the fiscal year affected performance.」

    For the new WEB business, the delayed full-scale launch of operations continued to affect performance as a factor behind the shortfall against plan in the third quarter.
  23. FY2018-Q2MaterialisedAnnual report

    「Although the Group proceeded in parallel with establishing its internal structure and transferring operations, the transfer of operations and integration of business systems took longer than expected, and the full-scale launch of operations required additional time, causing performance to fall short of plan.」

    The risk of delayed monetization of a new business materialized in the WEB Business, with the prolonged transfer of operations and systems integration resulting in a shortfall against plan.
  24. FY2017RestatedAnnual report

    「The Group is pursuing new businesses with the aim of securing stable earnings and achieving sustainable corporate growth. Depending on their nature, these businesses may require expenditures on research and development, capital investment and securing personnel, and because a new business requires a certain period from launch until it generates stable earnings, it may adversely affect the Group's operating performance during that period.」

    The costs of research and development, capital investment and securing personnel for new businesses, as well as the period required to monetize them, continue to be identified as risks.
  25. FY2017-Q3WorsenedAnnual report

    「We expanded sales of inspection equipment mainly in China and Southeast Asia. We actively exhibited at trade shows held in various regions of China and sought to acquire new customers, resulting in a substantial increase in the number of projects under inquiry. However, revenue fell short of plan because project sizes were reduced or projects were frozen, and because responding to customer requirements took longer, preventing sales from being completed.」

    Although inquiries for inspection equipment being developed as a new source of revenue increased, projects did not progress to sales because they were reduced or frozen and responding to customer requirements took longer, worsening the factors causing the shortfall against plan.
  26. FY2017-Q2RestatedAnnual report

    「We expanded sales of inspection equipment mainly in China and Southeast Asia. We actively exhibited at trade shows held in various regions of China and sought to acquire new customers, resulting in a substantial increase in the number of projects under inquiry. However, revenue fell short of plan because the order timing for many projects was pushed back to the third-quarter consolidated accounting period or later.」

    Although inquiries for inspection equipment being developed as a new source of revenue increased, the timing of orders for many projects was pushed back to the third quarter and beyond, and the shortfall against plan has continued.
  27. FY2017-Q1MaterialisedAnnual report

    「As a result, although revenue exceeded that of the previous quarter, the order timing for many projects that had been scheduled for receipt was pushed back to the third quarter of the fiscal year and beyond, causing revenue to fall short of plan.」

    For inspection equipment being developed as a new source of revenue, the timing of orders for planned projects was pushed back to the third quarter and beyond, resulting in a shortfall against plan.
  28. FY2016First statedAnnual report

    「Because a new business requires a certain period from launch until it generates stable earnings, it may adversely affect the Group's operating performance during that period.」

    The costs of research and development, capital investment and securing personnel during the development of new growth businesses, as well as the time required to monetize them, are identified as risks.
Moved together

"Establishing a New Growth Driver" moved the same way as this thread, in the same document, in 11 of its 31 moves.

11109877★123456
  1. ★This thread
  2. 1Establishing a New Growth Driver11×
  3. 2Continuing Business Structure Reform and Shifting Revenue Sources10×
  4. 3Restoring Corporate Value Growth through the ReGrowth2016 Plan9×
  5. 4Declining demand for information appliance manufacturers and weakening earning power of test media8×
  6. 5New Revenue Generation through Research and Development, Manufacturing and Sales in the Nanomaterials Business7×
  7. 6Shift to a Profitable Business Structure and Achievement of the Consolidated Operating Profit Plan7×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Almedio's next results are scheduled for 2026-11-02. Read the earnings preview It last moved in the Earnings of 2026-11-02: "Mitigated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.